Latest Breaking News On - Parker institute - Page 1 : comparemela.com

Perioperative Nivolumab Regimen Improves EFS, Resection Rates in Stage III N2/non-N2 NSCLC

Neoadjuvant nivolumab/chemotherapy, followed by surgery and adjuvant nivolumab, significantly improved EFS in stage III N2 and stage III non-N2 NSCLC.

Guardant Health to Present Studies at 2024 ASCO Annual Meeting Highlighting Contributions of Its Blood Tests and Real-World Data to Advancing Precision Oncology and Cancer Screening

Head-To-Head Contrast: Inovio Pharmaceuticals (NASDAQ:INO) vs. Delcath Systems (NASDAQ:DCTH)

Delcath Systems (NASDAQ:DCTH – Get Free Report) and Inovio Pharmaceuticals (NASDAQ:INO – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, dividends, analyst recommendations and valuation. Earnings & Valuation This table compares Delcath […]

CRISPR-based mapping uncovers 'switches' for immune genes central to health

Healthy T cells are the foundation of a balanced immune system. They can spring into action to fight off infections or cancer, but keep from becoming so activated that they hurt the very cells they re meant to protect, as is the case in autoimmune diseases.

Exploring Vaccine Approaches for Immunoprevention in Low-Grade Glioma

Hideho Okada, MD, PhD, discusses cancer immunoprevention through the lens of vaccine approaches in patients with low-grade glioma.